Arcutis Biotherapeutics (ARQT) Net Equity Issued and Repurchased (2020 - 2024)

Arcutis Biotherapeutics' Net Equity Issued and Repurchased history runs 5 years deep, the most recent figure standing at $3.1 million for Q4 2024.

• In Q4 2024, Net Equity Issued and Repurchased changed 0.0% year-over-year to $3.1 million; the TTM figure through Sep 2025 stood at $3.1 million (down 98.12% YoY), while the FY2024 annual figure was $161.7 million, changed N/A from the prior year.
• Net Equity Issued and Repurchased for Q4 2024 stood at $3.1 million, down from $161.7 million in the prior quarter.
• The five-year high for Net Equity Issued and Repurchased was $207.5 million in Q1 2021, with the low at -$45000.0 in Q2 2022.
• The 5-year median for Net Equity Issued and Repurchased is $14.5 million (2022), against an average of $74.0 million.
• The sharpest annual moves came in 2022 and 2024: Net Equity Issued and Repurchased sank 93.01% in 2022, then changed 0.0% in 2024.
• Arcutis Biotherapeutics' Net Equity Issued and Repurchased stood at $128.4 million in 2020, then surged by 61.65% to $207.5 million in 2021, then tumbled by 100.02% to -$45000.0 in 2022, then surged by 6988.89% to $3.1 million in 2023, then changed by 0.0% to $3.1 million in 2024.
• Business Quant data shows ARQT's Net Equity Issued and Repurchased at $3.1 million in Q4 2024, $161.7 million in Q1 2024, and $3.1 million in Q4 2023.